The letter, and what is on the page today
The agency reviewed this site in August 2025 and wrote in September. It quoted five variants of one claim shape, all of them saying the compounded product contains the same active ingredient as a named brand drug, and concluded that the claims imply the products are the same as an FDA-approved product when they are not.
A warning letter is a disclosure, not a finding of guilt, and this roster does not treat one as a reason to exclude a seller or to score it down. Fourteen of the ninety-five sellers here carry one, and the number, the date and a link to the agency's own text sit on this row.
What is unusual here is not the letter. It is that we searched the visible text of the product page a year later and the cited sentence is still there, twice. And a phrase the letter did not quote sits beside it: the product is described as an FDA compliant compounded version of the two brands. That reads as a stronger claim than the one the agency objected to, not a weaker one.
We are reporting what is on the page on one date. We are not asserting anything about whether the company has responded to the agency or what the agency has done since; neither is published where we could read it.
Two discounts, two very different sizes
Both product cards use the same design: a struck-through figure, a lower selling figure, and a line saying the price starts at the lower one and is lower than a stated number of leading brands.
The discounts are nothing like each other. On the semaglutide card the selling price is well under half the anchor. On the tirzepatide card it is a small trim off it. Same design, same wording, radically different meaning.
Neither card carries a plan term. There is no ladder, no commitment length, and nothing saying what the figure becomes on the second fill. The asterisk beside the price resolves to the standard compounding disclaimer rather than to a plan condition. That is why this row does not score for price stability.
What the paperwork names, and what it does not
The Terms name the affiliated medical practice as the provider of the professional services, which is a real disclosure. They also state the automatic-renewal billing term plainly: you are billed on each renewal period until cancellation. Most sellers here leave that to the checkout.
No individual clinician appears anywhere. No pharmacy is named — the pages say FDA-regulated compounding pharmacies and our partner pharmacies, which are categories. Sixty-nine of the ninety-five sellers here name no compounding pharmacy, and fifty-one name nobody who prescribes.
The Terms give a postal address for the company twice, in two different contact blocks, with the same street number and street and two different postcodes. That is small, and it is the kind of small that tells you how carefully the document was assembled.
There is no state list. We read the homepage, both product pages and the Terms; none names a served state or an exclusion. Fifty-eight of the ninety-five sellers here publish no service area at all.
Membership: not stated, and the census is attached
This roster records a membership as absent only when a seller says so. Here the word membership returns zero matches in the extracted visible text of four pages, including a Terms document running to more than thirty-five thousand characters.
What the Terms do describe is automatic billing on each renewal period until cancellation, which is a billing mechanic rather than a statement about a separate fee. Twenty-five of the ninety-five sellers here say nothing either way about a membership or programme fee, and this is one of them.
So the honest answer to what a month costs here is the price on the card, plus anything the company has not told you about. That is not an accusation. It is the shape of the disclosure.
Bioverse's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $129/moA discounted figure against a struck anchor, with no term stated: "$289 $129/mo" on the product card and "Starts at $129/month. Lower than 12 leading brands.*" beneath it. The asterisk resolves only to the standard compounding disclaimer, not to a plan length. | September 2026source |
| Tirzepatide (compounded) | $399/moSame card shape, much smaller discount: "$449 $399/mo" and "Starts at $399/month. Lower than 12 leading brands.*" ⚠ The semaglutide anchor falls 55% to its selling price and the tirzepatide anchor falls 11%, which is a large difference in the meaning of the same design. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 95 providers reviewed here are paid partners today; the other 91 are not. See how this works.
See Bioverse's current price →Good fit if
- Readers who want a figure for both compounded drugs published on their own pages without an intake.
- Buyers who want the pre-discount anchor printed beside the selling price rather than seeing only the lower number.
- People who want the automatic-renewal billing term stated in the Terms rather than discovered after the first charge.
- Anyone who wants the affiliated medical practice named.
Look elsewhere if
- Anyone weighing what a seller's product claims are worth. The exact sentence the FDA objected to in September 2025 was still on the product page a year later, alongside a stronger one it did not quote.
- Readers who need to know what the price becomes after the first fill. Neither card carries a plan term of any kind.
- Buyers who want the compounding pharmacy or an individual clinician named.
- Anyone who wants the membership question answered. Across four pages the word does not appear.
- Readers who need their state confirmed. No coverage list exists anywhere on the site.
How this review was verified
- Re-read the homepage, both product pages and the Terms of Use on 6 September 2026 rather than carrying any figure across from the research file that nominated this seller.
- Read the FDA warning letter in full, took the claim sentences it quotes, and searched for them in the extracted visible text of the product page. The cited claim appears twice, and a phrase the letter does not quote appears beside it.
- Fetched the warning letter URL and confirmed it returns a real page, with a nonsense warning-letter path on the same host in the same run returning 404, so the citation is not a minted URL.
- Ran a word-bounded census for membership across four pages, including a Terms document of more than thirty-five thousand characters, and found zero occurrences.
- Compared the two discounts as ratios rather than describing them both as discounts, which is how the difference in their size became visible.
- Printed the status, byte size and effective URL of every fetch, compared the effective path to the requested one, and ran a nonsense path against this host in the same run, which returned 404.
- Extracted every figure from a Python html.parser pass over text nodes only, with residual markup asserted absent.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. Untitled letters are published separately and were not searched.